Journals / Tüberküloz ve Toraks / 2013 / Cilt: 61 - Sayı: 2

The investigation of angiotensin converting enzyme I/D and plasminogen activator inhibitor-1 4G/5G polymorphisms in venous thromboembolism patients

Venöz tromboembolili hastalarda anjiyotensin dönüştürücü enzim I/D ve plazminojen aktivatör inhibitör-1 4G/5G gen polimorfizmlerinin araştırılması

Pages
88–95
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: These findings revealed that there is no relationship between these polymorphisms and the development of venous thromboembolism, but large-scale studies are need to be done.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Deep venous thrombosis and pulmonary embolism, known as venous thromboembolism and seen as a fairly common multifactorial diseases.
📊
Key Findings & Data:In this study we aimed to investigate the role of angiotensin converting enzyme insersion/deletion (ACE I/D) and plasminogen activator inhibitor-1 4G/5G (PAI-1 4G/5G) polymorphism in the development of disease.
💡
Conclusion & Impact:Conclusion: These findings revealed that there is no relationship between these polymorphisms and the development of venous thromboembolism, but large-scale studies are need to be done.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Deep venous thrombosis and pulmonary embolism, known as venous thromboembolism and seen as a fairly common multifactorial diseases. Differ between populations due to genetic factors, several polymorphisms associated with venous thromboembolism was conducted. As a result of these studies the relationship between disease development and polymorphism is not clear yet. In this study we aimed to investigate the role of angiotensin converting enzyme insersion/deletion (ACE I/D) and plasminogen activator inhibitor-1 4G/5G (PAI-1 4G/5G) polymorphism in the development of disease. Materials and Methods: In our study, DNA isolated from 80 venous thromboembolism patients and 79 control groups was used. While the classical polymerase chain reaction method used to investigate the ACE I/D polymorphism, the polymerase chain reaction based on allele-specific amplification was used for the detection of PAI-1 4G/5G polymorphism. Results: As a result, there were no significant statistical differences for ACE I/D and PAI-1 4G/5G polymorphism among patient and control groups (p> 0.05). Conclusion: These findings revealed that there is no relationship between these polymorphisms and the development of venous thromboembolism, but large-scale studies are need to be done.

Özet

Giriş: Derin ven trombozu ve pulmoner emboli, venöz tromboembolizm olarak da bilinen oldukça yaygın görülen multifaktöriyel hastalıklardır. Genetik faktörlerin popülasyonlar arası farklılık göstermesi nedeniyle venöz tromboemboli ile ilişkili birçok polimorfizm çalışması yapılmıştır. Yapılan bu çalışmalar sonucunda, hastalık gelişimi ile polimorfizmler arasındaki ilişki net olarak bilinmemektedir. Çalışmamızda venöz tromboemboli ile ilişkili genetik faktörler arasında yer alan anjiyo- tensin dönüştürücü enzim insersiyon/delesyon (ACE I/D) ve plazminojen aktivatör inhibitör-1 4G/5G (PAI-1 4G/5G) poli- morfizmlerinin hastalık gelişimindeki rolünü araştırmayı amaçladık. Materyal ve Metod: Çalışmamıza, 80 venöz tromboemboli hastası ve 79 kontrol birey dahil edildi. ACE I/D polimorfizminin araştırılmasında klasik polimeraz zincir reaksiyonu yöntemi kullanılırken, PAI-1 4G/5G polimorfizminin belirlenmesinde al- lel spesifik amplifikasyon yöntemine dayanan polimeraz zincir reaksiyonu yöntemi kullanıldı. Bulgular: Çalışmamızda, hasta grubu ile kontrol grubu arasında ACE I/D ve PAI-1 4G/5G polimorfizmi açısından istatistiksel olarak anlamlı bir fark bulunmadı (p> 0.05). Sonuç: Elde ettiğimiz bulgularda, bu gen polimorfizmleri ile venöz tromboemboli oluşumuna yatkınlık arasında ilişki bulunmamıştır. Daha fazla venöz tromboemboli hastasının değerlendirildiği ve ilişkisi olabilecek diğer gen polimorfizmlerinin araştırıldığı çalışmalara ihtiyaç vardır.

🔖

Cite This Article

TORUN, D., TUNCA, Y., KAYA, H., KOZAN, S., KARKUCAK, M., SALİFOĞLU, H. (2022). The investigation of angiotensin converting enzyme I/D and plasminogen activator inhibitor-1 4G/5G polymorphisms in venous thromboembolism patients. Tüberküloz ve Toraks, Cilt: 61 - Sayı: 2, 88–95. https://ajindex.com/articles/618639

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Fatini C, Gensini F, Sticchi E, Battaglini B, Prisco D, Fedi S, et al. ACE DD genotype: an independent predisposition factor to venous thromboembolism. Eur J Clin Invest 2003
  2. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Pat- wardhan NA, Jovanovic B, et al. A population-based perspec- tive of the hospital incidence and case-fatality rates of deep ve- in thrombosis and pulmonary embolism. Arch Intern Med 1991
  3. Munhoz TP, Scheibe RM, Schmitt VM. Angiotensin converting enzyme (ACE) DD genotype: relationship with venous throm- bosis. Rev Bras Hematol Hemoter 2005
  4. Forster AJ, Wells PS. The rationale and evidence for the treat- ment of lower-extremity deep venous thrombosis with throm- bolytic agents. Curr Opin Hematol 2002
  5. Deligezer U, Akisik E. Gene polymorphism analysis using LightCycler fluorescence PCR technique: determine the distri- bution of MTHFR C677T gene polymorphism in patients with myeloid leukemia in children and adults. Turkish Journal of Oncology 2004
  6. Karaca E. Investigation of Interleukin 10 Gene Polymorphisms in Patients with Coronary Artery (thesis). Izmir: Ege Univer- sity, Institute of Health Sciences
  7. Hsiao FC, Hsu LA. Meta-analysis of association between inser- tion/deletion polymorphism of the angiotensin I-converting enzyme gene and venous thromboembolism. Clin Appl Thromb Hemost 2011
  8. Sisli E. Evaluation of patients with venous thromboembolism in clinical quality, risk factors and genetic mutations (thesis). İzmir: Dokuz Eylul University Faculty of Medicine
  9. Caprini JA, Goldshteyn S, Glase CJ, Hathaway K. Thrombop- hilia testing in patients with venous thrombosis. Eur J Vasc Endovasc Surg 2005
  10. Oguzulgen IK, Yilmaz E, Demirtas S, Erkekol FO, Ekim N, De- mir N, et al. The role of plasminogen activator inhibitor-1 poly- morphism, factor-V-Leiden, and prothrombin-20210 mutations in pulmonary thromboembolism. Clin Appl Thromb Hemost 2009
  11. Rigat B, Hubert C, Corvol P, Soubrier F. PCR detection of the insertion/deletion polymorphism of the human angiotensin converting enzyme gene (DCP1) (dipeptidyl carboxypeptida- se 1). Nucleic Acids Res 1992
  12. Muetze S, Eggermann T, Leeners B, Birke C, Kuse S, Ortlepp JR, et al. The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is not associated with HELLP syndrome. J Thromb Thrombolysis 2009
  13. Tsantes AE, Nikolopoulos GK, Bagos PG, R